Banks targeted in long-running class actions over flexible commission schemes for car dealers are resisting the plaintiffs’ bid to amend their pleadings to “get around” the defence that certain claims are time-barred.
A judge has granted a limited stay of an injunction against US sports merchandise Fanatics after AFL merchandise maker FanFirm won its case alleging the US company knew about its ‘Fanatics’ trade marks.
AFL merchandise maker FanFirm has won a trade mark case against US sports merchandise giant Fanatics, with a judge finding it knew about the Australian company’s ‘Fanatics’ trade marks when it chose its corporate name.
Energy retailer Origin Energy has hit back at a trade mark infringement suit filed by internet provider Origin Net, arguing that its mark should be revoked and accusing Origin Net of misleading and deceptive conduct.
A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.
Convenience chain 7-Eleven has defeated Seven Network’s challenge to its bid to trade mark ‘7-Select’ for a new brand of products targeting younger shoppers, with an IP Australia delegate finding consumer confusion was not likely.
After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceutical’s patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.
The sole director of a small software company can’t act for his business in defending against an intellectual property case brought by digital titan Google, despite his plea to the court that his firm did not have the financial means to hire lawyers.
Construing an “ambiguous” order from the Full Federal Court, a judge has ordered a fresh trial in a trade secrets case that touched on the permissible scope of law firms’ involvement in drafting expert reports.
Novartis unit Sandoz has won its bid to stay a case by rival Lundbeck, including orders for damages previously calculated at $26.3 million and counting, despite having succeeded at the High Court in a dispute over its patent for blockbuster antidepressant Lexapro.